Trump admin set to announce using Tylenol while pregnant could raise autism risk
President Trump is set to make a groundbreaking announcement on Monday regarding the potential link between Tylenol use during pregnancy and the risk of developing autism, according to sources familiar with the situation. The Trump administration is expected to advise pregnant women to avoid using the over-the-counter pain medication unless they have high fevers, as a precautionary measure.
In addition to this warning, officials are also expected to discuss the exploration of using leucovorin, a drug typically used in cancer and anemia treatment, as a potential treatment for autism. This marks a significant shift in the approach to addressing autism and could have far-reaching implications for individuals affected by the condition.
President Trump has been teasing this announcement for several days, hinting at a major breakthrough in understanding and potentially treating autism. In a recent speech at conservative influencer Charlie Kirk’s funeral, he expressed his excitement about the upcoming news conference, stating, “I think we found an answer to autism.”
The administration’s decision to address the potential risks associated with Tylenol use during pregnancy and to explore alternative treatment options like leucovorin reflects a commitment to advancing research and improving outcomes for individuals with autism. This announcement is expected to spark discussions and further research in the medical community, potentially leading to new insights and advancements in the field of autism research and treatment.
As the details of this announcement unfold, it will be important to closely monitor the reactions and responses from the medical community, advocacy groups, and individuals affected by autism. The potential implications of these findings could have a significant impact on how autism is understood and treated in the future, opening up new possibilities for improved care and support for individuals with the condition.
